Ming Lim
Hematology & Oncology · Charleston, SCNPI 1184855751
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $74,826 of the $93,924 with a category attached, or 79.7%. 10 manufacturers reported payments, led by Sanofi at 42.5% of the total. Among hematology & oncology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 89 payments — averaging $1055.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$40K
- HEMA Biologics, LLC$14K
- AstraZeneca$13K
- E.r. Squibb & Sons, L.L.C.$12K
- Takeda Pharmaceuticals U.S.A., Inc.$5K
- Biomarin Pharmaceutical Inc.$3K
- plus $7K from 4 others
Across 72 payments — averaging $3433.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$189K
- Sobi, Inc$49K
- Dova Pharmaceuticals$9K
What the payments were for
- Consulting fees$74,82680%
- Speaking & faculty fees$4,9005%
- Grants$3,1963%
- Travel & lodging$8,4459%
- Food & beverage$2,5393%
- Education$60%
- Gifts$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 32 | $39,957 |
| HEMA Biologics, LLC | 28 | $13,795 |
| AstraZeneca | 7 | $13,144 |
| E.r. Squibb & Sons, L.L.C. | 5 | $11,678 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $5,061 |
| Biomarin Pharmaceutical Inc. | 4 | $3,478 |
| Novo Nordisk | 3 | $3,196 |
| Dova Pharmaceuticals | 2 | $3,000 |
| Octapharma USA, Inc. | 2 | $443 |
| Bayer | 2 | $173 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,924 in reported general payments places this provider in the 95th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 32 | $27,053 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Charleston
- George GeilsCharleston$76K
- Alexander ColtoffCharleston$51K
- Irl GreenwellCharleston$33K
- David EllisonCharleston$33K
- Shelly ShandCharleston$19K
- Nicholas SchmidtCharleston$18K
- George KeoghCharleston$18K
- Brian LingerfeltCharleston$15K
- James OrcuttCharleston$12K
- Robert StuartCharleston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.